IL6R and non-Hodgkin lymphoma: In this scenario, considering the prominent role of B-cells in primary Sjögren’s disease’s pathogenesis, we proposed the upregulation of miR-155, BAFF-R, and IL-6R as potential B-cell activation biomarkers capable of identifying patients who were more likely to experience NHL development in a cohort of primary Sjögren’s disease patients not exhibiting the canonical risk factors.